Oxford BioTherapeutics (OBT) has entered into a multi-year collaboration with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

OBT’s recently launched enhanced proprietary OGAP®-Verify discovery platform enables greater sensitivity and thereby the selection of targets with improved attributes for drug development.

Under the terms of the agreement, targets are identified via the OGAP®-Verify discovery platform and will be validated through the research collaboration. Any further research, development and commercialization efforts against these targets will be driven by Roche. OBT will receive up to USD 36 million upfront payments from Roche and may be eligible to receive milestone payments potentially exceeding US$1 billion, plus product royalties on net sales.

“We are proud to partner with Roche, a global leader in oncology, to accelerate the application of novel cancer targets identified through our proprietary discovery platform, OGAP-Verify. This collaboration builds on our efforts to enhance, validate and advance the discovery of oncology targets, and we look forward to leveraging Roche’s deep expertise to translate these insights into potential new treatments for patients. Our discovery philosophy is very patient centric and Roche’s strength to integrate pharma and diagnostics is unique in the industry,” said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics.

“We are excited to enter into this strategic collaboration with OBT. By combining Roche’s expertise in discovering and developing transformative therapeutics with OBT’s innovative target discovery platform, we aim to unlock new possibilities in cancer treatment. This partnership underscores our commitment to advancing potentially first-in-class antibody-based therapeutics. Together, we aim to accelerate the development of innovative therapies that address major unmet patient needs in oncology,” said Boris L. Zaïtra, Head of Corporate Business Development at Roche.